ECM
SRPT icon

Ensemble Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Ensemble Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-13,800
Closed -$768K – 33
2017
Q4 		$768K Buy
+13,800
New +$731K 0.14% 29
2017
Q2 		– Sell
-10,000
Closed -$296K – 41
2017
Q1 		$296K Buy
+10,000
New +$309K 0.07% 36

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Ensemble Capital Management's SRPT Position: Q1 2018 in Review

Ensemble Capital Management sold out of Sarepta Therapeutics (SRPT) in Q1 2018, closing a stake of 13,800 shares — an estimated $768K sold.

Ensemble Capital Management first reported a position in SRPT in Q1 2017 and held it in 2 quarters. The position peaked at $768K in Q4 2017. 269 funds tracked by Wall St. Rank hold SRPT as of Q1 2018.

  • Ensemble Capital Management reported no remaining Sarepta Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Ensemble Capital Management sold 13,800 Sarepta Therapeutics shares in Q1 2018, an estimated $768K.
  • Ensemble Capital Management first reported a position in Sarepta Therapeutics in Q1 2017 and held it in 2 quarters.
  • Ensemble Capital Management's Sarepta Therapeutics position peaked at $768K in Q4 2017.
  • 269 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2018.

Based on Ensemble Capital Management's 13F filing for Q1 2018, filed 15 May 2018.